Skip links


Doctoral Network

TRAJECTORY is an interdisciplinary and intersectoral research and training consortium project funded by the French National Research Agency (ANR) and consisting of 14 DCs, 12 beneficiaries and 22 associated partners brought together under the 2023 Marie Skłodowska-Curie Actions (MSCA) Doctoral Networks (DN) call. In case of funding, the common goal of the different TRAJECTORY stakeholders will be to offer a training programme in different sectors across Europe in order to educate highly qualified PhD students and to enhance their long-term employability in the field of tumour heterogeneity.


Consulting, branding, web, training



Graphic chart & logotype

Brainstorming meeting in Marseille with all  beneficiaries. Proposal for a communication and dissemination plan. Proposals for training programs (public outreach & dissemination) and new partnerships selected within the KOM network (training, workshop, secondment).

4 versions to fit the different stages of the consortium (networking v.0, Launch v.1.0, recruitment v.2.0, final v.3.0)

Videos presenting the training programme by the consortium's key players

Training the next generation of researchers to model and target intratumour heterogeneity (ITH) in cancer relapse.

Christophe GINESTIER, Inserm Project coordinator – Brainstorming meeting, Marseille, September 2023

Deciphering the biology of tumour relapse and developing optimised therapeutic strategies to better treat patients

Nowadays the leading cause of cancer death in patients with solid tumors is the occurrence of local or distant recurrences after the first lines of treatment. Cancer relapses have a significant enrichment in treatment-resistance cells compared to primary tumors. This is because therapeutic pressure imposes additional stresses that contribute to tumor evolution and the acquisition of resistance . Different mechanisms of failure can explain our difficulties to treat relapsing patients. First, each solid tumor is composed of cancer cells heterogeneous in terms of their genetic, epigenetic, transcriptional and translational states that evolve under treatment pressure . If advances in genomic technologies, single-cell sequencing and spatial transcriptomics have allowed to depict a thorough ITH portrait of primary tumors, very little has been done to characterize cancer relapse ITH. Leveraging transitions dynamics between cellular states appears as a potential therapeutic strategy to target tumor relapses. Second, preclinical models are often not established in relapsed conditions whereas early phase clinical trials are implemented in relapsing diseases, where patients have already received one or several lines of therapy.

Eduard BATLLE, IRB Barcelona Beneficiary – Brainstorming meeting, Marseille, September 2023

A bespoke graphic charter



Have a project in mind?

Looking for collaboration?
I’m interested in
working together
+33 662 220 024
Learn more about KOM
Send a message.
This website uses cookies to improve your web experience.